Subjects:
Free Research Articles
Topics:
follicular lymphoma

On page 2060 in the 28 April 2016 issue, there is an omission in Table 2. In column 2, the information for duvelisib (IPI-145), “PI3K-δ inhibitor,” should read “PI3K-δ and PI3K-γ inhibitor.” The corrected Table 2 is shown below. The error has been corrected in the online version, which now differs from the print version.

Table 2

Investigational agents in relapsed FL

AgentClassificationNORR, %CR, %Duration, 1-y PFS, %Reference
Lenalidomide Immunomodulator 45 53 20 55 69 
Lenalidomide + rituximab 46 76 39 80 
Duvelisib (IPI-145) PI3K-δ and PI3K-γ inhibitor 13 69 38 80 70 
Ibrutinib BTK inhibitor 40 28 5 50 71 
Venetoclax (ABT-199) BCL-2 inhibitor 29 38 14 40 72 
Polatuzumab vedotin + rituximab Anti-CD79b antibody-drug conjugate 45 73 33 63 73 
Obinutuzumab Anti-CD20 monoclonal antibody 74 45 12 65 74 
AgentClassificationNORR, %CR, %Duration, 1-y PFS, %Reference
Lenalidomide Immunomodulator 45 53 20 55 69 
Lenalidomide + rituximab 46 76 39 80 
Duvelisib (IPI-145) PI3K-δ and PI3K-γ inhibitor 13 69 38 80 70 
Ibrutinib BTK inhibitor 40 28 5 50 71 
Venetoclax (ABT-199) BCL-2 inhibitor 29 38 14 40 72 
Polatuzumab vedotin + rituximab Anti-CD79b antibody-drug conjugate 45 73 33 63 73 
Obinutuzumab Anti-CD20 monoclonal antibody 74 45 12 65 74 
View Large
© 2016 by The American Society of Hematology
2016
Sign in via your Institution